Lakefront Biotherapeutics reported EUR3.29B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
argenx SE USD 10.03B 1.35B Jun/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
Genmab DKK 12.52B 139M Jun/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
GRIFOLS EUR 20.28B 191M Sep/2026
Hikma Pharmaceutical USD 5.67B 117M Dec/2025
Incyte USD 7.29B 585.39M Sep/2026
Merck EUR 53.66B 975M Sep/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Novartis USD 117.15B 4.88B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 130.29B 1.23B Sep/2026
UCB EUR 18.16B 971M Dec/2025
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026